Literature DB >> 19752410

Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.

Forest W Arnold1, A Scott LaJoie, Guy N Brock, Paula Peyrani, Jordi Rello, Rosario Menéndez, Gustavo Lopardo, Antoni Torres, Paolo Rossi, Julio A Ramirez.   

Abstract

BACKGROUND: To define whether elderly patients hospitalized with community-acquired pneumonia (CAP) had better outcomes if they were treated with empirical antimicrobial therapy adherent to the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) guidelines for CAP.
METHODS: This was a secondary analysis of the CAPO International Cohort Study database, which contained data from a total of 1725 patients aged 65 years or older who were hospitalized with CAP. Data from June 1, 2001, until January 1, 2007, were analyzed from 43 centers in 12 countries including North America (n = 2), South America (n = 4), Europe (n = 4), Africa (n = 1), and Southeast Asia (n = 1). Initial empirical therapy for CAP was evaluated for guideline compliance according to the 2007 IDSA/ATS guidelines for CAP. Time to clinical stability, length of stay (LOS), total in-hospital mortality, and CAP-related mortality for each group were calculated. Comparisons between groups were made using cumulative incidence curves and competing risks regression.
RESULTS: Among the 1649 patients with CAP, aged 65 years or older, 975 patients were given antimicrobial regimens adherent to the IDSA/ATS for CAP guidelines, while 660 patients were treated with nonadherent regimens (465 patients were "undertreated"; 195 were "overtreated"). Adherence to guidelines was associated with a statistically significant decreased time to achieve clinical stability compared with nonadherence: the proportion of patients who reached clinical stability by 7 days was 71% (95% confidence interval [CI], 68%-74%) and 57% (95% CI, 53%-61%) (P < .01), respectively. Guideline adherence was also associated with shorter LOS (median adherence LOS, 8 days; interquartile range [IQR], 5-15 days; median nonadherence LOS, 10 days; IQR, 6-24 days) (P < .01) and decreased overall in-hospital mortality (8%; 95% CI, 7%-10% vs 17%; 95% CI, 14%-20%) (P < .01).
CONCLUSION: Implementation of national guidelines at the local hospital level will improve not only mortality and LOS of elderly patients hospitalized with CAP but also time to clinical stability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752410     DOI: 10.1001/archinternmed.2009.265

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  28 in total

1.  Adoption of a national antimicrobial guide (SWAB-ID) in the Netherlands.

Authors:  Emelie C Schuts; Caroline M van den Bosch; Inge C Gyssens; Bart-Jan Kullberg; Maurine A Leverstein-van Hall; Stephanie Natsch; Fre Sebens; Martha B Adams; Richard Drew; Jan M Prins
Journal:  Eur J Clin Pharmacol       Date:  2015-10-22       Impact factor: 2.953

2.  Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence.

Authors:  V Spoorenberg; J M Prins; E E Stobberingh; M E J L Hulscher; S E Geerlings
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

3.  Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study.

Authors:  Sara Tomczyk; Seema Jain; Anna M Bramley; Wesley H Self; Evan J Anderson; Chris Trabue; D Mark Courtney; Carlos G Grijalva; Grant W Waterer; Kathryn M Edwards; Richard G Wunderink; Lauri A Hicks
Journal:  Open Forum Infect Dis       Date:  2017-06-20       Impact factor: 3.835

4.  Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support?

Authors:  Torsten T Bauer; Tobias Welte; Richard Strauss; Helge Bischoff; Klaus Richter; Santiago Ewig
Journal:  Lung       Date:  2013-05-05       Impact factor: 2.584

Review 5.  How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia.

Authors:  Forest W Arnold
Journal:  Drugs Aging       Date:  2017-01       Impact factor: 3.923

Review 6.  Management of community-acquired pneumonia in older adults.

Authors:  Antonella F Simonetti; Diego Viasus; Carolina Garcia-Vidal; Jordi Carratalà
Journal:  Ther Adv Infect Dis       Date:  2014-02

7.  Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations.

Authors:  T C Jenkins; S A Stella; L Cervantes; B C Knepper; A L Sabel; C S Price; L Shockley; M E Hanley; P S Mehler; W J Burman
Journal:  Infection       Date:  2012-11-17       Impact factor: 3.553

8.  Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.

Authors:  Christopher R Frei; Matthew J Labreche; Russell T Attridge
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

9.  Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993-2005.

Authors:  Gregory W Ruhnke; Marcelo Coca-Perraillon; Barrett T Kitch; David M Cutler
Journal:  Med Care       Date:  2010-12       Impact factor: 2.983

10.  Barriers to guideline-concordant antibiotic use among inpatient physicians: A case vignette qualitative study.

Authors:  Daniel Livorsi; Amber R Comer; Marianne S Matthias; Eli N Perencevich; Matthew J Bair
Journal:  J Hosp Med       Date:  2015-10-06       Impact factor: 2.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.